Abstracts tagged "Bone density"

Abstract Number: 2143 • ACR Convergence 2024
Analysis of Effectiveness and Safety of Romosozumab in Patients with Very High Risk of Fracture in a Spanish Population
Marina soledad Moreno Garcia¹, Roxana González Mazario², yedra uson Rodriguez³, Erardo meriño Ibarra⁴, Emilio Giner⁵, Juan Carlos Cobeta García⁶, Marilia Arce Benavente⁷, maria Dolores Fábregas canales⁸, Julia Ullier Bellmunt³, Giuliano Boselli³, pilar martinez Valles⁷, Jorge Juan Fragío Gil⁹, carlos Vazquez Galeano⁷ and Ana Turrion Nieves¹⁰, ¹hospital Miguel Servet . Zaragoza, Zaragoza, Aragon, Spain, ²Hospital General de Valencia, Valencia, Comunidad Valenciana, Spain, ³hospital miguel servet, zaragoza, Aragon, Spain, ⁴Hospital San Jorge Huesca, zaragoza, ⁵Hospital Royo Villanova, Teruel, Spain, ⁶Hospital Ernest Lluch, zaragoza, ⁷hospital miguel servet, Zaragoza, ⁸Hospital de Barbastro, Huesca, Spain, ⁹Hospital General Universitario, Valencia, Comunidad Valenciana, Spain, ¹⁰Rheumatology Department, Hospital Universitario Virgen de la Vega, Salamanca, Spain
Background/Purpose: Excluding clinical trials, there is limited evidence on the effect of 12 months of romosozumab treatment on increasing bone mineral density (BMD) in real-world…
Abstract Number: 1066 • ACR Convergence 2024
Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Krista Topalsky¹, Lee Arphai², Mary Ellen Amos², Amanda Mertz², Christopher Blum³, Timothy Godbey², Lori Leonard², Maya Mattar⁴, Elizabeth Cable² and Robert Wenzell², ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²Cleveland VA Medical Center, Cleveland, OH, ³Cleveland VA Medical Center, Cleveland, ⁴Louis Stokes VA medical Center, Mayfield Heights, OH
Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
Abstract Number: 2226 • ACR Convergence 2024
Site-specific Differences in the Association of Non-vertebral Major Osteoporotic Fractures and Rheumatoid Arthritis
John Chen¹, Malini Chandra², Laura Carbone³, John Schousboe⁴, Elisha Garcia² and Joan Lo², ¹Kaiser Permanente Oakland Medical Center, Oakland, CA, ²Kaiser Permanente, Oakland, CA, ³Augusta University, Augusta, GA, ⁴University of Minnesota, Minneapolis, MN
Background/Purpose: Rheumatoid arthritis (RA) and osteoporosis are both chronic, potentially debilitating conditions that frequently co-occur, affecting millions of people annually. Among those with osteoporosis, RA…
Abstract Number: 1084 • ACR Convergence 2024
Osteoporosis and Osteopenia Diagnosed by Dual-Energy X-Ray Absorptiometry Are Not Increased in Patients with Gout
Karla Miller¹, grant Cannon¹, Kyle Register², Nadia Grant² and Naomi Schlesinger², ¹University of Utah and Salt Lake City VA, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Controversy exists surrounding the association of gout with osteoporosis diagnosis or incident fragility fractures. Dual-Energy X-Ray Absorptiometry (DXA) scan is the gold standard for…
Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakow Medical Centre, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
Abstract Number: 1616 • ACR Convergence 2024
Vitamin D Supplementation in the Prevention of Severe Adverse Effects Caused ByGlucocorticoids: Study from the ARTESER Registry of Giant Cell Arteritis
Gaston Ariel Ghio¹, Marta Domínguez-Álvaro², Ricardo Blanco-Alonso³, Santos Castañeda⁴, Iñigo Hernández-Rodríguez⁵, Elisa Fernández-Fernández:⁶, Maite Silva-Diaz⁷, Joaquin María Belzunegui:⁸, Clara Moriano⁹, Julio Sánchez-Martín¹⁰, Javier Narvaez-García¹¹, Eva Galindez¹², Anne Riveros Frutos¹³, Francisco Ortiz Sanjuán¹⁴, Tarek Carlos Salman Monte:¹⁵, Margarida Vasques Rocha:¹⁶, Carlota L Iñiguez:¹⁷, Alicia García Dorta¹⁸, Clara Molina Almela¹⁹ and María Alcalde Villar:²⁰, and ARTESER Project Collaborative Group, ¹Hospital Universitari Mutua Terrassa, Terrassa, Catalonia, Spain, ²Sociedad Española de Reumatología, Madrid, Spain, ³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶La Paz University Hospital, Alcalá de Henares, Madrid, Spain, ⁷Complejo Hospitalario Universitario A Coruña, A Coruña, Spain, ⁸H de Donostia, Donostia-San Sebasti, Spain, ⁹Hospital León, LEON, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹Hospital Universitario de Bellvitge, Barcelona, Spain, ¹²Hospital Universitario de Cabueñes, Bilbao, Spain, ¹³Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ¹⁴Hospital Universitario de Cabueñes, Gijón, Asturias, Spain, ¹⁵Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Lucus Augusti, Galicia, Spain, Galicia, Spain, ¹⁸Rheumatologist, La Laguna, Spain, ¹⁹Consorcio Hospital General Universitario de Valencia, Valencia, Comunidad Valenciana, Spain, ²⁰Hospital Universitario Severo Ochoa Leganés, Madrid, Spain, Madrid, Spain
Background/Purpose: Glucocorticoids (GC) are the gold standard for the treatment of giant cellarteritis (GCA). However, these drugs, when used at high doses and for prolonged…
Abstract Number: 2114 • ACR Convergence 2024
CT and DXA Bone Fragility Evaluation After Bariatric Surgery
Marine FAUNY¹, Marion Halin², Edem Allado², Laurent Brunaud², Claire Nomine Criqui², Eliane Albuisson², Isabelle Chary-Valckenaere³, Damien Loeuille⁴ and Didier Quilliot², ¹CH TOUL, Toul, Lorraine, France, ²Nancy University Hospital, Vandoeuvre, Lorraine, France, ³Nancy University Hospital, Vandœuvre-lès-Nancy, Lorraine, France, ⁴Phd, Nancy Vandoeuvre, Lorraine, France
Background/Purpose: Bariatric surgery could impact bone metabolism and induce significant changes, leading to increased bone resorption and an increased risk of fractures.The primary objective was…
Abstract Number: 1996 • ACR Convergence 2023
Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Karla Miller¹, Melissa Steffen², Kimberly McCoy², Michelle Mengeling², Heather Davila², Shylo Wardyn² and Samantha Solimeo², ¹University of Utah School of Medicine, Salt Lake City, UT, ²Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA
Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Richard Eastell¹, Bente Langdahl², Yoon-Sok Chung³, Rafal Plebanski⁴, Edward Czerwinski⁵, Eva Dokoupilova⁶, Jerzy Supronik⁷, Jan Rosa⁸, Anna Rowińska-Osuch⁹, Ki-Hyun Baek¹⁰, Audrone Urboniene¹¹, Sohui Ahn¹², Younghee Rho¹² and Jisuk Ban¹², ¹University of Sheffield, Sheffield, United Kingdom, ²Aarhus University Hospital, Aarhus, Denmark, ³Ajou University Hospital, Suwon, South Korea, ⁴Klinika Zdrowej Kosci, Łódź, Poland, ⁵Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, ⁶Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁷OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ⁸Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, ⁹ETG Warszawa, Warszawa, Poland, ¹⁰Yeouido ST. Mary's Hospital, Seoul, South Korea, ¹¹JSC Saules seimos medicinos centras, Kaunas, Lithuania, ¹²Samsung Bioepis, Incheon, South Korea
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
Abstract Number: 2000 • ACR Convergence 2023
Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study
Mai Kawazoe¹, Kaichi Kaneko², Shotaro Masuoka³, Soichi yamada³, Zento Yamada³, Sei Muraoka³, Karin Furukawa¹, Hiroshi Sato³, Eri Watanabe³, Keiko Koshiba³, Izumi Irita³, Miwa Kanaji³ and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ³Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…
Abstract Number: 2003 • ACR Convergence 2023
Effects of Abaloparatide on Cortical and Trabecular Compartments by 3D-DXA in Men with Osteoporosis
Ruban Dhaliwal¹, John Boxberger², Yamei Wang², Bruce Mitlak², Ludovic Humbert³ and Neil Binkley⁴, ¹Massachusetts General Hospital, Boston, MA, ²Radius Health, Inc., Boston, MA, ³3D-Shaper Medical, Barcelona, Spain, ⁴University of Wisconsin Osteoporosis Clinical Research Program, Madison, WI
Background/Purpose: Abaloparatide (ABL) increases BMD in men with osteoporosis. In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) trial, DXA-measured BMD change with…
Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
Abstract Number: 2011 • ACR Convergence 2023
Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
Nicholas Rossi¹, Aamir Saeed², Aqib Khan³, Hamzah Amin², Ummaz Nadeem², Zain Sultan³ and Marwan Bukhari², ¹University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom
Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Jia-Feng Chen¹, Tien-Tsai Cheng² and Hong-Yo Kang³, ¹Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ²Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, ³Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
Abstract Number: 2318 • ACR Convergence 2023
The Association Between Systemic Lupus Erythematosus (SLE) and Bone Mineral Density (BMD) Polygenic Risk Scores with Lumbar Spine BMD Z-score: A Retrospective Cohort Study
Vrati Mehra¹, Daniela Dominguez², Nicholas Gold², Andrea Knight², Deborah Levy², Fangming Liao², Eleanor Pullenayegum², Amer Shammas², etienne Sochett², Reza vali², Declan Webber³, Earl Silverman⁴ and Linda Hiraki², ¹The Hospital for Sick Children & University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Toronto, ON, Canada, ³University of Toronto, Mississauga, ON, Canada, ⁴Silverman, Toronto, ON, Canada
Background/Purpose: Childhood-onset systemic lupus erythematosus patients < 18 years (cSLE) are at risk for reduced bone mineral density (BMD) due to disease activity and chronic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].